<DOC>
	<DOCNO>NCT02108418</DOCNO>
	<brief_summary>1 . To evaluate pharmacokinetics ( PK ) relative bioavailability TG-2349 , give new capsule formulation original formulation oral solution , single oral dose 400 mg feed condition healthy volunteer . 2 . To evaluate safety tolerability TG-2349 healthy volunteer . 3 . To evaluate ethnic difference PK safety East Asian Caucasian volunteer .</brief_summary>
	<brief_title>Study Evaluate PK , Relative Bioavailability Safety TG-2349 With Single Oral Dose Under Fed Condition Healthy Volunteers</brief_title>
	<detailed_description>TG-2349 oral solution investigate phase I/IIa study ( study number : TG-2349-01 ) healthy volunteer patient chronic hepatitis C ( CHC ) infection . The study demonstrate TG-2349 safe well-tolerated give healthy volunteer single oral dos 800 mg , five-consecutive daily oral dos 600 mg. Co-administration TG-2349 food result significant increase bioavailability , therefore concomitant food intake dosing recommend . To advance clinical development TG-2349 , new capsule formulation develop replace current TG-2349 oral solution . The objective study ( study number : TG-2349-02 ) evaluate PK relative bioavailability TG-2349 , give new capsule formulation original formulation oral solution , single oral dose 400 mg feed condition healthy volunteer , evaluate safety , tolerability , ethnic difference TG-2349 capsule formulation .</detailed_description>
	<criteria>Inclusion Criteria Screening 1 . East Asian Caucasian subject , male female , 18 40 year age inclusive 2 . Body mass index ( BMI ) range 19.0 30.0 kg/m2 body weight ≥ 50 kg inclusive 3 . In general good physical mental health status basis medical history review , medical evaluation include vital sign physical examination , 12lead ECG , laboratory result screen 4 . For female , one follow criterion must fulfil : ( 1 ) At least 1 year post menopausal , ( 2 ) Surgically sterile , ( 3 ) Willing use doublebarrier method ( intrauterine device [ IUD ] plus condom , spermicidal gel plus condom ) contraception screen 30 day last dose study drug ; 5.Males must willing use reliable form contraception ( use condom partner fulfil criterion ) screen 30 day last dose study drug 6.Willing abstain caffeine xanthinecontaining beverage ( include coffee tea ) , alcohol , grapefruit juice , Seville oranges stayonsite period 7.Willing able provide write informed consent Exclusion Criteria Screening 1 . Positive serological test IgM antiHAV antibody , HbsAg , antiHCV antibody screen 2 . Positive ELISA test HIV1 HIV2 screen 3 . Any following abnormal laboratory value screen : Hemoglobin ( Hb ) &lt; 12.0g/dL woman &lt; 13.0g/dL men , white blood cell count ( WBC ) &lt; 3,000 cells/mm3 , absolute neutrophil count &lt; 1,500 cells/mm3 , platelet count &lt; 100,000 cells/mm3 , serum creatinine ≥ 2 mg/dL , ALT AST level ≥ 2 xULN , total bilirubin ≥ 1.5 xULN , INR ( International Normalized Ratios prothrombin time ) ≥1.5 xULN 4 . Any abnormal laboratory value consider clinically significant Investigator screen 5 . QTcF great 450 msec female 430 msec male screen 6 . History renal , hepatic impairment , stomach intestinal surgery resection , malabsorption syndrome 7 . History seizure , epilepsy , cardiovascular , diabetes , cancer ( except basal cell carcinoma ) 8 . History family history prolong QT interval family history sudden cardiac death young age ( &lt; 30 year ) 9 . History drug allergy hypersensitivity , especially sulfa drug 10 . History evidence abuse alcohol , barbiturate , amphetamine , recreational , narcotic drug use within 6 month prior first dose study drug administration 11 . Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment psychiatric illness , history suicide attempt depression 12 . Anemia blood/plasma donation within 30 day prior first dose study drug administration 13 . Pregnant breastfeed 14 . Use tobacco nicotinecontaining product within 30 day prior first dose study drug administration 15 . Use concomitant medication , include herbal remedy dietary supplement ( except paracetamol/acetaminophen , ibuprofen , hormonal contraceptive ) within 14 day prior first dose study drug administration 16 . Received investigational drug within 30 day prior first dose study drug administration Exclusion Criteria First Admission 1 . Any following abnormal laboratory value admission : Hb &lt; 12.0g/dL woman &lt; 13.0g/dL men , WBC &lt; 3,000 cells/mm3 , absolute neutrophil count &lt; 1,500 cells/mm3 , platelet count &lt; 100,000 cells/mm3 , serum creatinine ≥ 2 mg/dL , ALT AST level ≥ 2 xULN , total bilirubin ≥ 1.5 xULN , INR ≥ 1.5 xULN 2 . Any abnormal laboratory value consider clinically significant Investigator admission 3 . Any clinically significant abnormality 12lead ECG QTcF great 450 msec female 430 msec male admission 4 . Positive urine drug screen breath alcohol test admission 5 . If female , positive serum pregnancy test admission 6 . Acute illness within 2 week prior dose , unless approve Sponsor 's Medical Monitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>